Fwd: Special Edition - Lifestyle Changes and GLP-1

---------- Forwarded message ----------
From: Diabetes In Control Special GLP-1 Edition <diabetes@topica.email-publisher.com>
Date: Sun, Sep 9, 2012 at 2:00 PM
Subject: Special Edition - Lifestyle Changes and GLP-1
To: palashbiswaskl@gmail.com

To ensure that you never miss an issue, please whitelist us. September 13, 2012 (Recommend Us) Feature GLP-1 Analogs, Appetite and Satiety The Use of GLP-1 Analogs and Lifestyle Changes GLP-1 Agonists and Lifestyle Changes: A Recipe for Success Homerun Slides: Clinical presentation library GLP-1 Analogs and Lifestyle Modifications Editor's Note Seven years ago the first line therapy for the onset of type 2 diabetes was lifestyle changes and often we would take up to a year of trying various exercise and diet methods before we started medication. Because diabetes has reached epidemic proportions we are much more aggressive in our treatment strategies, and we start medication, usually metformin, at diagnosis along with lifestyle changes. Although the metformin helps with glucose levels our patients still fail miserably when it comes to lifestyle changes. This week our team of talented interns explore how the use of GLP-1 analogs can help your patients succeed with their diet and exercise programs. Your partner in diabetes care, Dave Joffe Editor-in-chief Feature GLP-1 Analogs, Appetite and Satiety Cierra Harden PharmD Candidate 2013 LECOM School of Pharmacy, Bradenton Obesity is a major risk factor for the development of diabetes as well as predisposing individuals to hypertension and dyslipidemia. In the United States, 54.8% of persons with diabetes are obese, and 85.2% are overweight or obese1. All of these conditions when combined together increase a person's risk for cardiovascular disease which is one of the leading causes of morbidity and mortality in type 2 diabetes2. Many of these patients with multiple comorbidities often have trouble reaching their physician's prescribed treatment goals. While lifestyle modifications are still the gold standard they often seem unattainable and unrealistic to the obese and overweight patient. It has been well documented that weight control can help improve insulin sensitivity and help restore beta-cell function. The use of GLP-1 analogs in therapeutic regimens may help T2DM patients reach their goals faster and easier. Click here for GLP-1 Analogs, Appetite and Satiety The Use of GLP-1 Analogs and Lifestyle Changes Alan Mathis PharmD Candidate 2013 University of Florida GLP-1 analogs not only improve plasma glucose levels and reduce HbA1c, but also improve metabolic effects such as reduction in BMI, waist circumference, and improve cardiovascular health. Diabetic patients, especially with type 2 diabetes, tend to have poor diets and sedentary lifestyle leading to a high prevalence of overweight and obesity. The characteristics of unhealthy nutrition habits, sedentary lifestyle, and visceral obesity, with diabetes, contribute to metabolic disorders such as hypertension and dyslipidemia which increase the patient's risk for cardiovascular disease. Lifestyle changes such as increasing activity and altering eating behaviors are important in the treatment of type 2 diabetes. In fact, the American Diabetes Association recommends patients diagnosed with type 2 diabetes start lifestyle changes and metformin. Click here for The Use of GLP-1 Analogs and Lifestyle Changes GLP-1 Agonists and Lifestyle Changes: A Recipe for Success Andre McMahon, PharmD Candidate UF College of Pharmacy Achieving glycemic control is a critical goal in the management of patients with type 2 diabetes mellitus (DM). Hyperglycemia contributes to the progression of DM by adversely affecting both the body's sensitivity to insulin and beta-cell function. Type 2 DM results from impaired insulin secretion. As beta-cell function continues to decline, the body progressively loses metabolic control and eventually leads to the need for insulin treatment. Thus, preserving the beta cells from declining in function plays a pivotal role in preventing type 2 DM and altering the course of the disease. Glucagon-like peptide-1 (GLP-1) analogs, which include exenatide (Byetta®), liraglutide (Victoza®) and exenatide extended-release (Bydureon®), have been made available with the purpose of stimulating insulin secretion with an incretin-mimetic mechanism. Coupling GLP-1 analogs with lifestyle modifications can lead to treatment success in type 2 DM through management and prevention of hyperglycemia and targeting beta-cell dysfunction.1 Click here for GLP-1 Agonists and Lifestyle Changes: A Recipe for Success Homerun Slides: Clinical presentation library GLP-1 Analogs and Lifestyle Modifications Prepared by Margarita Stanosyan, Doctor of Pharmacy Candidiate, LECOM College of Pharmacy, this terrific collection of Homerun Slides will give you everything you need to know about GLP-1 Analogs and how they help promote and work with the lifestyle changes your patients need to be addressing.   Click here for GLP-1 Analogs and Lifestyle Modifications Diabetes In Control has over 11500 studies & articles in our archives. This newsletter is not associated with the American Diabetes Association Thank you to Our Advertisers Copyright 1999-2012 Diabetes In Control Deerfield, Illinois 60015 To ensure that you never miss an issue, please whitelist us.

	Unsubscribe | Update Profile | Confirm | Complain | Forward